Milnacipran: A new treatment for fibromyalgia syndrome

Journal of Pharmacy Technology

Volumn 26, Issue 3, 2010, Pages 129-135

  Hale, Katherine S ^a  

^a UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DIGOXIN; DOXEPIN; DULOXETINE; FLUOXETINE; GABAPENTIN; LITHIUM; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; MORPHINE; NORADRENALIN; OPIATE; PARACETAMOL; PREGABALIN; SAVELLA; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE;

ABDOMINAL PAIN; ANTICHOLINERGIC SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; CONSTIPATION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; NAUSEA; PAIN; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; SYNDROME; SYSTOLIC BLOOD PRESSURE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 77954527197     PISSN: 87551225     EISSN: None     Source Type: Journal    
DOI: 10.1177/875512251002600306     Document Type: Review

References (24)

1. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep 2003;7:362-8. DOI 10.1007/s11916-003-0035-2
2. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160-72.
3. Ablin J, Neumann L, Buskila D. Pathogenesis of fibromyalgia - a review. Joint Bone Spine 2008;75:273-9. DOI 10.1016/j.jbspin.2007.09.010
4. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat 2008;4:1059-71.
5. Buckhardt CS, Goldenberg D, Crofford L, et al. Guideline for the management of fibromyalgia syndrome pain in adults and children. Glenview, IL: American Pain Society, 2005. www.guideline. gov/summary/summary.aspx?ss= 15&doc-id=7298&nbr=4342 (accessed 2010 Jan 14).
6. Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 1995;38:19-28. DOI 10.1002/art.1780380104
7. White KP, Harth M. Classification, epidemiology, and natural history of fibromyalgia. Curr Pain Headache Rep 2001;5:320-9. DOI 10.1007/s11916-001-0021-2
8. Russell IJ, Vaeroy H, Javors M, et al. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6. DOI 10.1002/art.1780350509
9. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-601. DOI 10.1002/art.1780371106 (Pubitemid 24345805)
10. Ablin JN, Cohen H, Buskila D. Mechanisms of disease: genetics of fibromyalgia. Rheumatology 2006;2:671-8. DOI 10.1038/ncprheum0349
11. Forseth KO, Gran JT. Management of fibromyalgia: what are the best treatment choices? Drugs 2002;62:577-92. DOI 10.2165/00003495-200262040-00003
12. Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Atzeni F. Treatment strategy in fibromyalgia syndrome: where are we now? Semin Arthritis Rheum 2008;37:353-65. DOI 10.1016/j.semarthrit.2007.08.008
13. Crofford LJ. Pain management in fibromyalgia. Curr Opin Rheumatol 2008;20:246-50. DOI 10.1097/BOR.0b013e3282fb0268
14. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA 2009;301:198-209. DOI 10.1001/jama.2008.944
15. Product information. Savella (milnacipran). New York, NY: Forest Pharmaceuticals, Inc., March 2009.
16. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl- aminocarbonyl-2- aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 1985;24:1211-9. DOI 10.1016/0028-3908(85) 90157-1
17. Puozzo C, Lens S, Reh C, et al. Lack of interaction of milnacipran with the cytochrome P450 isoenzymes frequently involved in the metabolism of antidepressants. Clin Pharmacokinet 2005;44:977-88. DOI 10.2165/00003088- 200544090-00007 (Pubitemid 41252846)
18. Branco JC, Perrot S, Bragee G, et al. Milnacipran for the treatment of fibromyalgia syndrome: a European multicenter, randomized, double-blind, placebo-controlled trial (abstract). Ann Rheum Dis 2008;67:251.
19. Clauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. Clin Ther 2008;30:1988-2004. DOI 10.1016/j.clinthera.2008.11.009
20. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:398-409. DOI 10.3899/jrheum.080734
21. Cios DA, Kim JE. Milnacipran: a serotonin and norepinephrine reuptake inhibitor for the management of fibromyalgia syndrome. Formulary 2009;44:197-202.
22. Peuch A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108. DOI 10.1097/00004850-199703000-00005 (Pubitemid 27286559)
23. Product information. Cymbalta (duloxetine). Indianapolis, IN: Eli Lilly and Company, November 2009.
24. Product information. Lyrica (pregabalin). New York, NY: Pfizer, Inc., December 2009.